Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Chemi S.p.A.

Status and phase: Completed; Phase 2

Conditions: Lymphorrhea

Treatments: Drug: LF-PB and Placebo; Drug: LF-PB; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01754285

LF-PB/11/04

Details and patient eligibility

About

This is a phase II, multicenter, double-blind, double-dummy, parallel-group, placebo-controlled, study to evaluate LF-PB versus placebo in female patients with brest cancer who are undergoing breast surgery with axillary lymphnode dissection.

Recruited patients will be randomly assigned to one of the following treatment groups: Placebo, LF-PB 10 mg, LF-PB 20 mg and LF-PB 30 mg.

Mode of administration is single intramuscular (IM) injection so the treatments arms are as follows:

Placebo: 2 injections of placebo LF-PB 10 mg: 2 injections = placebo + 10 mg LF-PB 20 mg: 2 injections = placebo + 20 mg LF-PB 30 mg: 2 injections = 10 mg + 20 mg

The study will randomize a total of 120 patients (30 per arm) in about 10 Italian Sites.

Enrollment: 114 patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Female aged 18 to 80 years inclusive
2. Body mass index (BMI) ≥18 kg/m2
3. Signed informed consent form
4. Diagnosis of BC
5. Undergoing breast surgery with ALND Note: Collagen powder or fibrin sealant are not permitted.
6. Negative serum pregnancy test for women of childbearing potential Note: Female patients of child-bearing potential should be advised to use adequate contraception if necessary during treatment with octreotide.
7. AST and alanine aminotransferase ALT <1.5 x the upper limit of normal
8. Ability to fully understand all study procedures and to comply with study visits scheduled for the duration of the study.

Exclusion criteria

1. Presence of any of the following conditions:

   1. Previous axillary surgery on the same armpit undergoing surgery in this study
   2. Previous chemotherapy or radiotherapy within five years from study drug administration
   3. Previous neoadjuvant therapy
   4. Recurrent BC on the same breast undergoing surgery in this study
   5. Diabetes
   6. Cholelithiasis
   7. Hypothyroidism. If patient is being administered Euritox/ Levothyroxine (or analogues) and levels of T3, T4 and TSH are confirmed to be within the normal ranges at screening, the patient can be enrolled in this study.
   8. Hepatitis
   9. Pregnant or lactating
   10. Human immunodeficiency virus or hepatitis B or C by screening serology

2. History of radiotherapy on the same breast or armpit undergoing surgery in this study.

3. History of anaphylaxis to study drug

4. Ascertained or presumptive hypersensitivity to the active principle and/or the ingredients of the study drug formulation

5. QTc interval extension at screening or baseline > 450 msec (as the mean of 3 consecutive readings 5 minutes apart)

6. Presence of any disease or use of concomitant medication known to increase the QT interval (see Appendix 2 for a list of such compounds)

7. Clinically significant or relevant abnormal medical history, vital sign, physical examination, ECG, or laboratory evaluation finding

8. Current or recurrent disease that could affect the results of the clinical or laboratory assessments required for the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

114 participants in 4 patient groups, including a placebo group

LF-PB 10 mg

Experimental group

Description:

2 IM injections = placebo + 10 mg

Treatment:

Drug: LF-PB and Placebo

LF-PB 20 mg

Experimental group

Description:

2 IM injections = placebo + 20 mg

Treatment:

Drug: LF-PB and Placebo

LF-PB 30 mg

Experimental group

Description:

2 IM injections = 10 mg + 20 mg

Treatment:

Drug: LF-PB

Placebo

Placebo Comparator group

Description:

2 IM injections of placebo

Treatment:

Drug: Placebo